Get Started

ACOG

NASD Alpha Cognition Inc
Nov 2, 2026 · 12:42 PM ET DELAYED Market Open

$8.57 ↓ -0.17 (-1.95%) Trading Down from the previous close of $8.74, $0.38 below the day’s high of $8.95

YTD change
+31.85%
vs 20-day SMA
-1.96%
vs 200-day SMA
+19.86%

Price ranges

Previous day
$8.71 $9.17
open $9.16 close $8.74
-$0.42 (-4.59%)
Today
$8.43 $8.95
open $8.85 now $8.57
-$0.28 (-3.16%)
Past week
$8.08 $9.35
from $8.34 now $8.57
+$0.23 (+2.76%)
Past month
$7.98 $9.37
from $9.10 now $8.57
-$0.53 (-5.82%)
This year
$4.50 $10.14
from $6.50 now $8.57
+$2.07 (+31.85%)

Price & Performance

+2.69 (+44.46%) / 6M

$5.15$6.80$8.44$10.09May 4Aug 3Oct 30

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral
  • The stock is 25.7% away from all-time highs of $11.54
  • ACOG is up 32% since the beginning of the year
  • ACOG is up 38% over the past 12 months
  • ACOG is down 6% over the past 1 month
  • 2% of all ACOG investors are betting against ACOG

ACOG reads neutral: price sits above one of the two key moving averages, the 12-month move is +53.3%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.4
Earnings momentum -19.4% Quarterly EPS growth
Quarterly change -19.4%

Valuation

P/E ratio N/A
Enterprise value $148.9M
Beta 1.39

Balance sheet & scale

IncomeN/A
Revenue$15.1M
Cash$41.4M
DebtN/A
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Administrative and Support and Waste Management and Remediation Services
Sub Sector Administrative and Support Services
Market cap $186.7M

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. It has additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal (“ALPHA-1062IN”) formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI, otherwise known as concussion) and ALPHA-0602, ALPHA-0702 & ALPHA-0802. The company was founded in 2000 and is headquartered in Grapevine, TX.

Competitor comparison

TickerCompany PriceChange
VISA.CAT VISA INC CDR CAD HG REG S $37.51 +0.73%
POW.CAT POWER CORP CDA $96.60 -1.40%
MA.CAT MASTERCARD INCORPORATED CDR CAD HEDGED $38.29 +0.16%
RBA.CAT RB GLOBAL INC $125.40 +1.47%
UBER.CAT UBER TECHNOLOGIES INC UBER TECH CAD HE $9.51 -0.83%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.